Company intelligence / Profile preview

Monaco Dudley

Monaco, Monaco

Ownership: Private
Development stage: Other

Overview

Monaco Dudley was a pharmaceutical company based in Monaco that specialized in the development of topical gynecological and dermatological treatments. The company is most notable for the research and development of promestriene, a synthetic estrogen analog used for the localized treatment of vaginal atrophy and related conditions. Promestriene was marketed under brand names such as Colpotrophine and Delipoderm. In 1999, the company was reportedly acquired by Merck & Co. (known as MSD outside the U.S. and Canada), which integrated its product portfolio into its broader women's health and dermatology divisions.

Therapeutic areas: Women's HealthDermatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Monaco Dudley.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Monaco Dudley.

Explore the full profile